

**THE EFFECT OF PREGNANCY ON THE ACTIVITY OF RHEUMATOID
ARTHRITIS AND ITS THERAPY**

Sultonov Ilkhom Islomovich

PhD., Assistant of Samarkand State Medical University

ABSTRACT: Rheumatoid arthritis (RA) often affects women of childbearing age, which determines a long-standing interest in studying the mutual effects of pregnancy and RA. In the first observation, described about 80 years ago, a decrease in the activity of the disease was noted in the absolute majority of pregnant women. In more recent prospective studies, it was shown that only 48-66% of pregnant women have clinical improvement during gestation, and postpartum exacerbation of RA is noted in 70% of patients, while most patients require drug therapy.

The aim of the study was to evaluate the dynamics of RA activity according to DAS28–CRP during pregnancy and after childbirth; to clarify the effect of RA activity at the beginning of gestation on the further course of the disease. To determine the need for drug therapy in pregnant women with RA.

Material and methods. Prospectively, in each trimester of gestation and for 12 months after delivery, it was followed 32 pregnancies in 29 women with reliable RA (ACR criteria of 1987).

Results and discussion. During pregnancy, 46% of RA patients had a decrease in disease activity. During 12 months, on average 1.5 months after delivery, 75% of patients had an exacerbation of RA. In patients with remission and low activity of the disease at the beginning of pregnancy, the activity of RA during the entire gestation period and 1 month after delivery remained significantly lower than in patients with moderate and high activity in the first trimester ($p=0.0008-0.04$). A similar trend was observed in patients with no arthritis at the time of conception (according to the survey). 23 (71.9%) in patients with signs of disease activity during pregnancy, anti-inflammatory therapy was intensified, against which DAS28-CRP decreased ($p=0.008$), while in the remaining 9 (28.9%), with low activity without drug intervention, it tended to increase. After childbirth, patients with high and moderate activity improved earlier ($p=0.008$), since they resumed therapy with basic anti-inflammatory (HDL) and genetically engineered drugs earlier biological drugs (GIBP) than in patients with remission and low activity during pregnancy. In the latter, the tendency to increase activity persisted until 3 months after childbirth. In 12 (37.5%) patients who became pregnant while taking HDL or GIBP and urgently canceled them due to pregnancy, disease activity in the I–III trimesters was significantly higher than in 20 (62.5%) cases when HDL and/or GIBP were not used or canceled in advance when planning pregnancy ($p<0.04$).

Conclusions. Remission or low activity of RA at the beginning of pregnancy is a predictor of low activity of the disease and minimization of drug therapy up to complete rejection of it throughout pregnancy. Without medical intervention, RA activity may tend to increase. Postpartum exacerbation of RA is also noted in patients who had remission and low RA activity before childbirth. The abrupt cancellation of HDL or GIBP in connection with the

onset of unplanned pregnancy contributes to an increase in the activity of RA already from the first trimester of gestation. Pregnancy should be planned by choosing stable anti-inflammatory therapy in advance.

Keywords: rheumatoid arthritis; pregnancy; rheumatoid arthritis activity; DAS28-CRP; anti-inflammatory therapy.

INTRODUCTION

Rheumatoid arthritis (RA) often affects women of childbearing age, which determines a long-standing interest in studying the mutual effects of pregnancy and RA. The first description of pregnancy in RA dates back to 1935, P.S. Hensch in a prospective study observed a decrease in disease activity in 20 patients with RA during 33 of 34 pregnancies. In 2011, a large review on pregnancy in RA was published. The authors report that the frequency of clinical improvement during gestation ranged from 66 to 91%, and exacerbation after childbirth was observed in 60-91% of patients. J.L. Nelson et al. in a study of 57 pregnancies in 41 women, remission of the disease was noted only in 39% of cases, and a decrease in activity in 21%. It should be emphasized that the activity of RA during pregnancy can also be influenced by ongoing therapy. The goal is to trace the dynamics of RA activity during pregnancy and after childbirth, using DAS28-CRP; to clarify the effect of RA activity at the beginning of gestation on the further course of the disease, to determine the need for drug therapy in pregnant women with RA.

MATERIALS AND METHODS OF RESEARCH

The work is based on the results of a prospective follow-up of 32 pregnancies in 29 women with reliable RA (ACR criteria 1987), 11 of them (38%) with juvenile RA (JURA). The patients were examined at 10-12, 20-22, 30-32 weeks of gestation, as well as 1, 3, 6 and 12 months after delivery. Most of the patients (n=25, or 78.1%) were included in the study starting from the first trimester of pregnancy, 3 more (9.4%) – from the second and 4 (12.5%) – from the third trimester. During the follow-up period, three women had repeated pregnancies (one of them is two repeat pregnancies), three of which were also included in this

study. In the case of a new pregnancy within 12 months after the previous birth, the observation of the previous case was considered completed. A new pregnancy was considered as a new case of pregnancy at the same control dates as the rest of the pregnancies.

At the time of inclusion in the study, the median age of patients was 29 [27; 31] years, the duration of the disease was 8 [4; 16] years, the age of onset of the disease was 19 [13; 25] years old. Seropositive for rheumatoid factor (RF) – n=18 (62.1%) and antibodies to cyclic citrullinated peptide (ADCP) – n=17 (58.6%) variants of RA prevailed, II and III radiological stages – n=21 (72.4%), I and II functional classes – n=25 (86.2%). 5 (17.2%) patients had a history of extra-articular manifestations of the disease: pericarditis (n=4), rheumatoid nodules (n=2) and polyneuropathy (n=1). One patient had amyloidosis of the internal organs. At the time of inclusion in the study, 15 (51.7%) patients were pre-pregnant; 18 (62.1%) of the surveyed were expecting the first birth, 11 (37.9%) – the second.

Nonsteroidal anti-inflammatory drugs (NSAIDs) were taken in anamnesis by 27 (93.1%) patients, 3 (9.4%) – including at the time of conception. In order to minimize the adverse effects on the fetus and the course of labor, NSAIDs were canceled no later than 30-32 weeks of pregnancy. Basic anti-inflammatory drugs (HDL) in the anamnesis was received by 26 (89.7%) patients. In 24 (75%) cases, they were canceled before pregnancy (the interval from the moment of cancellation to conception was 18 [10; 30] months), in 8 (25%) patients pregnancy occurred against the background of taking HDL, which were canceled immediately after the fact of pregnancy was established. Genetically engineered biological preparations (GIBP) was prescribed to 6 (20.7%) patients in the anamnesis. Four (12.5%) cases of pregnancy in three RA patients occurred against the background of GIBP therapy: adalimumab – 2 (6.3%), infliximab and tocilizumab – 1 (3.1%) each. At the time of conception, 19 (59.4%) of the subjects took glucocorticoids (HA) orally at a dose of 5 to 15 (Iu 5 [5; 10]) mg /day in terms of prednisone. The duration of taking GC before conception ranged from 7 months to 14 years (Me 58 [12; 90] months). In total, 2 (6.9%) patients with RA had not previously received drug therapy. At the time of conception, 6 (18.8%) RA patients were not taking medications. During the follow-up period, therapy was

adjusted according to indications. All patients underwent a comprehensive clinical and laboratory examination. The content of RF and C-reactive protein (CRP) was determined by immunonephelometric, ADC – electrochemiluminescent method.

In the previous article, we determined that the optimal method for assessing RA activity for this study is the DAS28-CRP index with its gradation: remission ≤ 2.6 points; low activity from 2.6 to 3.2; moderate activity from 3.2 to 5.1; high activity ≥ 5.1 . The increase or decrease in RA activity was interpreted based on the criteria of the European Anti-Rheumatic League (EULAR).

Statistical data processing was carried out using the Statistica 8.0 program (StatSoft, USA), including generally accepted methods of parametric and nonparametric analysis. The data are presented as a median of [25th; 75th percentiles]. The correlation analysis was performed using Spearman's method. Statistical the significance was determined as $p < 0.05$ (adjusted for Wilcoxon).

THE RESULTS AND THEIR DISCUSSION

1. Dynamics of RA activity according to DAS28-CRP during the observation period

The median DAS28-CRP significantly decreased during pregnancy ($p=0.005$), and increased after childbirth ($p=0.05$), then, by the 12th month after childbirth, it tended to decrease, but without statistical reliability. Remission or low activity of RA in the first trimester occurred in 13 (52%) patients, 12 (48%) had moderate or high activity. By the third trimester, the number of patients who had remission or low activity increased to 20 (62.6%), and the number of patients with moderate or high activity decreased to 12 (37.4%). 1 month after delivery, remission or minimal RA activity was determined in 14 (43.7%) cases, and the number of patients with high and moderate disease activity was maximum – $n=18$ (56.3%). Then, by the 12th month after delivery, the number of patients with low RA activity and

remission increased to 15 (57.7%), the number of patients with moderate activity decreased to 11 (42.3%), and high activity was not observed.

A decrease in RA activity was observed mainly during gestation: $n=9-10$ (36-35.7%). In the first month after childbirth, the maximum number of exacerbations was observed: 10 (31.3%) moderate and 2 (6.3%) significant ones. Upon further observation, the decrease and increase in RA activity were observed in approximately the same proportions.

A decrease in DAS28-CRP from the beginning of follow-up (I/II trimester) to the third trimester of gestation was observed in 13 (46.4%) patients, of whom 7 (25%) had a pronounced decrease. Moderate exacerbation of the disease during gestation was noted only in 3 (10.7%) cases. After the maximum exacerbation during the 1st month after childbirth ($n=12$, or 37.6%), then from the 1st to the 12th month, a decrease in disease activity was observed in 12 (46.2%), and a moderate exacerbation in 8 (30.8%) patients. When analyzing the postpartum activity of RA in each patient, it was noted separately that only 8 (25%) patients had no episodes

exacerbations for all 12 months after childbirth, while in 24 (75%) they were noted at least once during a postpartum visit. The median period from childbirth to the appearance of the first clinical signs of an exacerbation of RA was 1.5 [0.75; 2.5] months. Interestingly, in patients with seronegative RF variant of RA [of which 9 (81.8%) were from JURA] in the first trimester DAS28-CRP was significantly higher ($p=0.03$). At the same time CHBS, CHPS and the duration of morning stiffness in their joints were longer than in patients with seropositive RA, not only in the I, but also in the III trimester of pregnancy ($p=0.006-0.02$).

2. The effect of rheumatoid arthritis activity at the beginning of pregnancy on the subsequent course of the disease

In order to assess the effect of disease activity at the beginning of pregnancy on the further course of RA, the patients observed from the first trimester ($n=25$) were divided into two groups. The first group included 13 (52%) patients with remission ($n=10$) or low activity ($n=3$) in the first trimester; the second group included 12 (48%) patients with moderate ($n=8$) and high ($n=4$) disease activity. The selected groups were comparable in age and duration of RA. During the entire observation, the activity of the wound the 2nd group remained higher than in the 1st: up to 1 month after childbirth – significantly ($p=0.0008-0.04$), then – without statistical reliability. In group 1, DAS28-CRP fluctuated slightly during pregnancy with a tendency to increase in the second trimester, and in group 2 it progressively decreased throughout the gestational period. The decrease in disease activity in group 2 during pregnancy was more pronounced ($p=0.0008$). In the third trimester in group 1, remission was detected in 10 (76.9%), and in the 2nd - only in 3 (25%)

cases, low activity in group 2 - in 4 (33.3%) moderate activity in group 1 was observed in 3 (23.1%) cases, in group 2 - also in 3 (25%), and high activity was observed only in group 2 - in 2 (16.7%) patients.

During the 1st month after delivery, DAS28-CRP increased in both groups. By this time, lactation was suppressed in most patients with RA exacerbation and active antirheumatic therapy was resumed; thus, the further dynamics of disease activity was primarily due to the therapy. Therefore, by the 3rd month after childbirth, activity in the 2nd group decreased, and in the 1st, where active therapy began later, it increased slightly ($p=0.008$). Subsequently, the dynamics of DAS28-CRP in both groups was similar, and by the 12th month after delivery, the index values were practically the same. According to the medical history, the absence of arthritis at the time of conception was observed in 15 (46.9%) cases. The duration of the period of absence of arthritis before pregnancy was determined from the words of patients, and its median was 12 [6; 12] months (from 6 to 84 months). In these patients, DAS28-CRP throughout pregnancy and 1 month after delivery was significantly lower than in patients with arthritis at the time of conception ($p=0.0007-0.04$). At the same time, in patients who became pregnant against the background of the presence of arthritis, activity decreased, and in patients with the absence of arthritis at the time after conception, the activity of RA increased. This may be due to the increased attention of the doctor to patients with arthritis at the beginning of pregnancy and the appointment of adequate therapy immediately after childbirth, while the exacerbation of the disease in patients without arthritis at the beginning of pregnancy was less expected, and therapy after childbirth was prescribed to them later.

3. Therapy during the observation period

Only in 6 (18.8%) patients conception occurred against the background of the absence of drug therapy, in 5 (15.6%) cases there was no need for its appointment during the entire pregnancy and only in 1 (3.2%) – and within 12 months after delivery. In 7 (28%) patients with low RA activity or remission of the 25 patients observed from the first trimester of gestation, therapy did not change during pregnancy, while all 12 (48%) patients with moderate to high activity had increased anti-inflammatory therapy ($p=0.01$). The main drugs for activity control

RA during pregnancy were NSAIDs ($n=20$; 62.5%) and GC ($n=23$; 71.9%). At the same time, in 9 (28.1%) patients during pregnancy, the dose of HA increased, and 4 (12.5%) they were prescribed for the first time. In addition, during gestation, 16 (50%) patients required intra-articular and 6 (18.8%) - intravenous drip administration of HA. During childbirth, 20 (62.5%) patients with signs of RA activity were additionally parenterally injected with GC. After childbirth, due to increased disease activity, the need for HA ($n=24$; 75%) and NSAIDs ($n=27$; 84.4%) it was rising. If necessary, HDL therapy was resumed ($n=28$; 87.5%) and/or GIBP was added ($n=8$; 25%), and therefore intra-articular ($n=12$; 37.5%) and intravenous ($n=3$; 9.4%) administration of HA was required less often than during pregnancy. To clarify the contribution of drug therapy to changes in RA activity during and after pregnancy, we compared the dynamics of DAS28-CRP in patients

whose treatment regimen did not change during gestation ($n=9$; 28.9%) with patients whose anti-inflammatory therapy increased during pregnancy ($n=23$; 71.9%). In the gestational period in group 2 The median DAS28-CRP was expected to decrease, while as in the 1st group, there was some increase in it.

Thus, without medical intervention (Group 1) RA activity increased during pregnancy. After childbirth, an increase in disease activity was noted in both groups, requiring the addition of appropriate therapy, against which, by the time the observation was completed, the median DAS28- CRP decreased. To assess the effect of previous pregnancy therapy, we identified 12 (37.5%) patients whose unplanned pregnancy occurred on against the background of receiving HDL (n = 8; 25%) or GIBP (n= 4; 12.5%); 5 (41.7%) of them had no arthritis at the time of conception . After the withdrawal of these drugs due to pregnancy, the activity of the disease from the first to the third trimester was significantly higher in them than in 20 (62.5%) cases when HDL and/or GIBP were not used or were canceled in advance when planning pregnancy ($p<0,04$). In addition, the dose of HA was increased in these patients during pregnancy, as a result of which by the third trimester it was significantly higher than in patients with planned pregnancy ($p=0.04$). After childbirth, due to the exacerbation of RA in most patients, the difference in disease activity between these groups was minimal.

The results of this study confirm the well-known fact of a decrease in RA activity during gestation and its increase after childbirth. Remission or low activity of RA by the third trimester in our study was noted in 20 (62.6%) cases. However, we observed a decrease in RA activity during pregnancy less frequently (46.4%) than in most other studies (60–91%) [9–12]. This discrepancy may be due to differences in the initial activity of the disease in the observed patients. Attention was drawn to the significant contribution of anti-inflammatory therapy carried out during pregnancy in reducing the activity of the disease during this period. In cases where anti-inflammatory therapy was not performed or remained stable, RA activity

tended to increase during the gestational period. RA exacerbation developed within 12 months after delivery (1.5 months on average) in 75% of cases, and in the 1st

month - in 12 (37.6%) patients. Thus, high or moderate RA activity prevailed until the 6th month, which corresponds to the literature data. When assessing the effect of disease activity at the beginning of pregnancy on the further course of RA, it was noted that with moderate or high disease activity in the first trimester (or in the presence of arthritis at the time of conception), RA activity was higher during subsequent visits up to 1 month after delivery compared with patients with remission or low RA activity in the first trimester (or with the absence of arthritis at conception). At the same time In the latter, after childbirth, there was a tendency to increase the activity of RA, while in patients with active disease, DAS28-CRP decreased from the beginning of gestation. This is due to the early resumption of their active anti-rheumatic (including HDL and GIBP) therapy after childbirth. The presence of a tendency to exacerbation of RA after childbirth in patients with low activity at the beginning of pregnancy necessitates careful dynamic monitoring of their condition by a doctor and early appointment of adequate therapy after childbirth. Analysis of the effect of previous pregnancy the effect of therapy on the activity of the disease during pregnancy has shown that at conception against the background of taking HDL or GIBP activity of RA was significantly higher already from the first trimester of gestation until delivery. A decrease in activity

was noted only after the resumption of active antirheumatic therapy after childbirth. Thus, when planning pregnancy, RA patients should be recommended to select pregnancy-

compatible therapy in advance (to cancel HDL, if necessary, attaching GC) in order to avoid an exacerbation of the disease provoked by abrupt withdrawal of drugs.

CONCLUSIONS

1. During pregnancy, 46% of RA patients have a decrease in disease activity. After childbirth, 75% of patients experience an exacerbation of RA, on average after 1.5 months.
2. Anti-inflammatory therapy during pregnancy makes a significant contribution to reducing the activity of RA during this period. Without medical intervention, RA activity may tend to increase.
3. Remission or low activity of RA at the beginning of pregnancy is a predictor of low activity of the disease and minimization of drug therapy up to complete rejection of it throughout pregnancy.
4. Postpartum exacerbation of RA is noted, including in patients who had remission and low RA activity before childbirth. Such patients also need the increased attention of a doctor for the timely appointment of adequate therapy.
5. The abrupt cancellation of HDL or GIBP in connection with the onset of unplanned pregnancy contributes to an increase in the activity of RA already from the first trimester. Pregnancy should be planned by choosing stable anti-inflammatory therapy in advance.

LITERATURE

1. Ziyadullaev, S. K., Sultonov, I. I., Dushanova, G. A., & Akbarovna, K. S. (2021). The Effectiveness Of Pharmacotherapy For Dmards With Ra Depending On The C3435t Polymorphism Of The Mdr1 Gene. *Int. J. of Aquatic Science*, 12(3), 2908-2916.
2. Ilkhom, S. (2023). CAJAM–VOLUME 1. ISSUE 1. 2023. *Central Asian Journal of Advanced Medicine*, 1(01), 16-19.
3. Хамраева, Н. А., Султонов, И. И., & Хасанов, Ф. Ш. У. (2019). Кожные проявления у больных системной красной волчанкой. *Вопросы науки и образования*, (28 (77)), 128-131.
4. Тоиров, А. Э., Султонов, И. И., & Тоиров, Э. С. (2020). ЗНАЧЕНИЕ ДИСФУНКЦИИ ПОЧЕК У БОЛЬНЫХ ОСТРЫМ ИНФАРКТОМ МИОКАРДА НА ФОНЕ САХАРНОГО ДИАБЕТА 2-ГО ТИПА. *Вестник науки и образования*, (9-3 (87)), 86-91.
5. F. Sh. Xasanov, & I. I. Sultonov. (2023). RHEUMATOID ARTHRITIS TREATED WITH DMARDS AND CARDIOVASCULAR DISEASE RISK. *Oriental Journal of Medicine and Pharmacology*, 3(02), 45–52.
6. Khusainova, M. A., Vakhidov, J. J., Khayitov, S. M., & Mamadiyurova, M. M. (2023). Cardiac arrhythmias in patients with rheumatoid arthritis. *Science and Education*, 4(2), 130-137.
7. Khusainova, M. A. (2023). Comorbidity thyrotoxicosis with coronary heart disease. *Science and Education*, 4(5), 205-213.
8. Khusainova, M. A., Eshmatova, F. B., Ismoilova, K. T., & Mamadiyurova, M. M. (2023). METABOLIC SYNDROME IN RHEUMATOID ARTHRITIS AS A CRITERION

OF CARDIOVASCULAR RISK. *Oriental renaissance: Innovative, educational, natural and social sciences*, 3(1), 331-339.

9. Khusainova, M. A., Ergashova, M. M., Eshmamatova, F. B., & Khayitov, S. M. (2023). Features of quality of life indicators in patients with pneumonia. *Science and Education*, 4(2), 138-144.

10. Alisherovna, K. M., Ismatullayevich, M. A., & Nuriddinova, E. N. (2024). FEATURES OF HEART FAILURE IN PATIENTS WITH CORONARY HEART DISEASE AND THYROTOXICOSIS. *Ta'lim innovatsiyasi va integratsiyasi*, 19(4), 52-61.

11. Alisherovna, K. M., Yaxshiboyevich, U. M. R., & Yigitaliyevich, B. A. (2024). EVALUATION OF A NATRIURETIC PEPTIDE TO OPTIMIZE THE MANAGEMENT OF COMORBID PATIENTS WITH THYROTOXICOSIS AND HEART FAILURE. *Ta'lim innovatsiyasi va integratsiyasi*, 19(4), 62-70.

12. Alisherovna, K. M., Mansurovna, M. D., Erkinovna, N. D., Farxodovna, X. R., Toxirovna, M. M., Tolibovna, R. D., & Yorkinovna, E. N. (2024). ARTERIAL HYPERTENSION AND THYROID STATUS IN PATIENTS OF DIFFERENT AGES. *Ta'lim innovatsiyasi va integratsiyasi*, 19(4), 122-129.

13. Alisherovna, K. M., Erkinovna, S. D., Duskobilovich, B. S., & Samandarovich, T. H. (2024). ARTERIAL HYPERTENSION IN THYROTOXICOSIS AND REMODELING OF THE LEFT VENTRICLE OF THE HEART. *Ta'lim innovatsiyasi va integratsiyasi*, 19(4), 114-121.

14. Alisherovna, K. M., Erkinovna, S. D., Yazdonkulovna, X. M., & Zafarovna, C. M. M. (2024). ATRIAL FIBRILLATION IN THYROTOXICOSIS—DETERMINANTS OF DEVELOPMENT AND CONSERVATION. *Ta'lim innovatsiyasi va integratsiyasi*, 19(4), 103-113.

15. Alisherovna, K. M., Habibulloyevna, I. M., & Voxidovna, R. F. (2024). STRUCTURAL AND FUNCTIONAL FEATURES OF THE LEFT VENTRICLE IN PATIENTS WITH HEART FAILURE IN ISCHEMIC HEART DISEASE AND THYROTOXICOSIS. *Ta'lim innovatsiyasi va integratsiyasi*, 19(4), 71-81.

16. ALISHEROVNA, M. K., SHAXMAXMUDOVNA, S. Z., & TATLIBAYEVICH, Y. S. (2021). Effectiveness of Treatment of Chronic Heart Disease Insufficiency Depending on the Functional State of the Kidneys. *JournalNX*, 7(02), 240-333.

17. Alisherovna, K. M., Akmalovna, K. N., & Mamasoliyevna, D. N. (2022). Kidney dysfunction in chronic heart failure. *Texas Journal of Medical Science*, 13, 104-109.

18. Alisherovna, K. M., Kulmuxammatovich, Y. U., Boymamatovna, E. F., & Shokirovich, S. A. (2023). THE STATE OF NEUROPEPTIDE-CYTOKINE STATUS IN ISCHEMIC HEART DISEASE. *Spectrum Journal of Innovation, Reforms and Development*, 11, 42-50.

19. Alisherovna, K. M., Akramovna, I. K., & Yorkinovna, E. N. (2024). CLINICAL AND MORPHOLOGICAL CRITERIA OF COLITIS IN PATIENTS WITH CHRONIC ISCHEMIC DISEASE OF THE DIGESTIVE SYSTEM. *Ta'lim innovatsiyasi va integratsiyasi*, 18(6), 6-13.

20. Mamasoliyevna, D. N., Alisherovna, K. M., & Totlibayevich, Y. S. (2023). Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: the Facets of Conjugacy. *Miasto Przyszłości*, 35, 166-173.

21. Alisherovna, K. M., Davranovna, M. K., & Erkinovna, K. Z. (2024). Coronary heart disease and osteoporosis in postmenopausal women. *Spectrum Journal of Innovation, Reforms and Development*, 26, 40-45.